Total Payments
$625,767
2024 Payments
$44,488
Companies
21
Transactions
158
Payment Breakdown by Category
Consulting$378,029 (60.4%)
Other$204,955 (32.8%)
Travel$39,498 (6.3%)
Food & Beverage$1,899 (0.3%)
Research$1,386 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $378,029 | 65 | 60.4% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $203,105 | 7 | 32.5% |
| Travel and Lodging | $39,498 | 40 | 6.3% |
| Food and Beverage | $1,899 | 32 | 0.3% |
| Honoraria | $1,850 | 3 | 0.3% |
| Unspecified | $1,386 | 11 | 0.2% |
Payments by Type
General
$624,381
147 transactions
Research
$1,386
11 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| SANOFI US SERVICES INC. | $194,070 | 19 | $0 (2019) |
| SANOFI-AVENTIS U.S. LLC | $110,363 | 9 | $0 (2017) |
| Eli Lilly and Company | $69,889 | 14 | $0 (2024) |
| Bayer HealthCare Pharmaceuticals Inc. | $47,330 | 15 | $0 (2021) |
| E.R. Squibb & Sons, L.L.C. | $40,410 | 5 | $0 (2024) |
| Boehringer Ingelheim International GmbH | $31,264 | 14 | $0 (2024) |
| Relypsa, Inc. | $31,250 | 2 | $0 (2020) |
| Merck Sharp & Dohme LLC | $24,794 | 10 | $0 (2023) |
| Bard Peripheral Vascular, Inc. | $22,913 | 9 | $0 (2023) |
| AstraZeneca Pharmaceuticals LP | $17,342 | 21 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $44,488 | 6 | Eli Lilly and Company ($23,680) |
| 2023 | $41,951 | 19 | Bard Peripheral Vascular, Inc. ($22,913) |
| 2022 | $48,176 | 21 | Eli Lilly and Company ($28,373) |
| 2021 | $43,425 | 16 | Eli Lilly and Company ($12,000) |
| 2020 | $29,635 | 9 | E.R. Squibb & Sons, L.L.C. ($9,960) |
| 2019 | $248,454 | 37 | SANOFI US SERVICES INC. ($184,275) |
| 2018 | $22,303 | 38 | Eli Lilly and Company ($5,836) |
| 2017 | $147,335 | 12 | SANOFI-AVENTIS U.S. LLC ($110,363) |
All Payment Transactions
158 individual payment records from CMS Open Payments — Page 1 of 7
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/27/2024 | Boehringer Ingelheim International GmbH | — | Consulting Fee | Cash or cash equivalent | $4,760.00 | General |
| 09/13/2024 | Eli Lilly and Company | — | Consulting Fee | Cash or cash equivalent | $14,080.00 | General |
| 04/10/2024 | Boehringer Ingelheim International GmbH | — | Consulting Fee | Cash or cash equivalent | $4,440.00 | General |
| 04/03/2024 | Boehringer Ingelheim International GmbH | JARDIANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $1,858.23 | General |
| Category: DIABETES | ||||||
| 03/15/2024 | Eli Lilly and Company | — | Consulting Fee | Cash or cash equivalent | $9,600.00 | General |
| 01/18/2024 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $9,750.00 | General |
| 12/04/2023 | Bard Peripheral Vascular, Inc. | — | Consulting Fee | Cash or cash equivalent | $4,875.00 | General |
| 12/04/2023 | Bard Peripheral Vascular, Inc. | — | Consulting Fee | Cash or cash equivalent | $2,112.50 | General |
| 11/02/2023 | Bard Peripheral Vascular, Inc. | — | Consulting Fee | Cash or cash equivalent | $2,275.00 | General |
| 11/02/2023 | Bard Peripheral Vascular, Inc. | — | Consulting Fee | Cash or cash equivalent | $650.00 | General |
| 07/05/2023 | Bard Peripheral Vascular, Inc. | — | Consulting Fee | Cash or cash equivalent | $3,250.00 | General |
| 04/19/2023 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $5,985.00 | General |
| 04/18/2023 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $9,735.00 | General |
| 04/18/2023 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Travel and Lodging | In-kind items and services | $140.00 | General |
| 04/18/2023 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $35.00 | General |
| 03/21/2023 | Impulse Dynamics (USA) Inc. | OPTIMIZER (Device), OPTIMIZER | Food and Beverage | Cash or cash equivalent | $79.77 | General |
| Category: Cardiovascular Device | ||||||
| 03/20/2023 | ABIOMED | Impella (Device) | Food and Beverage | In-kind items and services | $36.24 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 03/15/2023 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Travel and Lodging | In-kind items and services | $639.13 | General |
| 03/15/2023 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Travel and Lodging | In-kind items and services | $159.85 | General |
| 03/15/2023 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $8.53 | General |
| 03/02/2023 | Bard Peripheral Vascular, Inc. | — | Consulting Fee | Cash or cash equivalent | $2,600.00 | General |
| 02/02/2023 | Bard Peripheral Vascular, Inc. | — | Consulting Fee | Cash or cash equivalent | $3,250.00 | General |
| 01/10/2023 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $2,220.00 | General |
| 01/03/2023 | Bard Peripheral Vascular, Inc. | — | Consulting Fee | Cash or cash equivalent | $2,275.00 | General |
| 01/03/2023 | Bard Peripheral Vascular, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,625.00 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effects of Sotagliflozin on Clinical Outcomes in Hemodynamically Stable Patients With Type 2 Diabetes | SANOFI US SERVICES INC. | $1,386 | 11 |
About Dr. Jeffrey Testani, M.D
Dr. Jeffrey Testani, M.D is a Cardiovascular Disease healthcare provider based in New Haven, Connecticut. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/27/2006. The National Provider Identifier (NPI) number assigned to this provider is 1588729750.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Jeffrey Testani, M.D has received a total of $625,767 in payments from pharmaceutical and medical device companies, with $44,488 received in 2024. These payments were reported across 158 transactions from 21 companies. The most common payment nature is "Consulting Fee" ($378,029).
Ad
Practice Information
- Specialty Cardiovascular Disease
- Location New Haven, CT
- Active Since 12/27/2006
- Last Updated 07/13/2016
- Taxonomy Code 207RC0000X
- Entity Type Individual
- NPI Number 1588729750
Products in Payments
- SOTAGLIFLOZIN (Drug) $295,401
- Non-Covered (Drug) $39,855
- Veltassa (Drug) $31,250
- JARDIANCE (Drug) $28,181
- NO PRODUCT DISCUSSED (Drug) $7,646
- Non-Covered $7,475
- FARXIGA (Drug) $5,543
- Product in Development (Device) $5,100
- ENTRESTO (Drug) $3,750
- SAR439954 (Drug) $1,386
- CardioMEMS HF System (Device) $151.91
- OPTIMIZER (Device) $79.77
- Impella (Device) $36.24
- CentriMag (Device) $23.58
- XARELTO (Drug) $11.85
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Cardiovascular Disease Doctors in New Haven
Henry Ward, M.d, M.D
Cardiovascular Disease — Payments: $404,260
Cardiovascular Disease $404,260
Dr. John Forrest, M.d, M.D
Cardiovascular Disease — Payments: $232,147
Cardiovascular Disease $232,147
Dr. Alexandra Lansky, Md, MD
Cardiovascular Disease — Payments: $205,439
Cardiovascular Disease $205,439
Dr. Hyung Chun, Md, MD
Cardiovascular Disease — Payments: $180,221
Cardiovascular Disease $180,221
Lissa Sugeng, Md, Mph, MD, MPH
Cardiovascular Disease — Payments: $106,815
Cardiovascular Disease $106,815
Eric Velazquez, M.d, M.D
Cardiovascular Disease — Payments: $103,971
Cardiovascular Disease $103,971